Following the Supreme Court opinion Dobbs v. Jackson Women’s Health Organization that overturned the longstanding Roe v. Wade and Planned Parenthood v. Casey, the constitutional right to abortion vanished. Almost immediately states began enacting and enforcing total or near total abortion bans. These bans threatened revocation of medical licensure for professionals who provided certain types of reproductive health care like abortions, as well as felony charges, fines, and other penalties for those that assist a pregnant person in obtaining reproductive health care. Some states also enacted laws that punish individuals who assist someone traveling out of state for reproductive health care. Although they are currently not being enforced, the specter of enforcement exists.
The rapid changes and uncertainty of those changes altered the delivery of reproductive health care in the United States. It also generated an inherent mistrust between health care providers and patients in states that have legal limits to seeking certain sexual and reproductive health services, primarily abortion. Patients who were seeking reproductive health care or who had already obtained reproductive health care would understandably be concerned and likely fearful about confiding in their providers with this information for fear of being reported to authorities for violating state law.
As a result, the HHS proposed to modify the original privacy rules to protect reproductive healthcare following the Dobbs decision. HHS felt it necessary to assure patients that their reproductive healthcare information would be safeguarded.
The standards for privacy of individually identifiable health information are regulated by the under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH Act). Effective June 25, 2024, the Department of Health and Human Services’ (HHS) issued the 2024 HIPAA Privacy Rule to Support Reproductive Health Care Privacy (2024 HIPAA Privacy Rule). It has two components that prohibits entities and their business associates from the following:
In addition, the 2024 HIPAA Privacy Rule
HHS defines reproductive health care broadly as health care “that affects the health of an individual in all matters relating to the reproductive system and to its functions and processes.”
Covered entities under HIPAA include health plans, health care clearinghouses, and health care providers who transmit any health information in electronic form related to complete health care transactions. Business associates are those who assist covered entities with their health care functions such as medical transcriptionists and third party administrators.
Anyone requesting PHI related to reproductive health will have to submit an attestation that the PHI is for health care oversight activities; judicial or administrative proceedings; law enforcement purposes; or disclosures about decedents (e.g., coroners). This attention is made under penalty of perjury.
All covered entities must comply with the rule’s final requirements by December 23, 2024.
HIPAA Privacy Rule To Support Reproductive Health Care Privacy
Final Rule HIPAA Privacy Rule to Support Reproductive Health Care Privacy
Reproductive Privacy Rule to Protect Both Patients and Physicians
Are you an
ObG Insider?
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. We no longer offer Hours.
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site